What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective | Zendy

HU Ying-lian | Zendy; Simiao Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Author(s) -

HU Ying-lian,

Simiao Chen

Publication year - 2021

Publication title -

journal of travel medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.985

H-Index - 59

eISSN - 1708-8305

pISSN - 1195-1982

DOI - 10.1093/jtm/taab026

Subject(s) - china , covid-19 , medicine , perspective (graphical) , government (linguistics) , set (abstract data type) , public relations , economic growth , virology , political science , outbreak , economics , programming language , linguistics , philosophy , disease , pathology , artificial intelligence , computer science , infectious disease (medical specialty) , law

Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research